Drugs / Pfs230D1-EPA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06507605 | Aug 2024 → Jan 2026 | malaria | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05135273 | Oct 2021 → Feb 2023 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pfs230D1-EPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05135273 ↗ |
| Modality | Vaccine | “Pfs230D1 conjugate vaccines” NCT06507605 ↗ |
| Route | Intramuscular | “all administered as an IM injection” NCT06507605 ↗ |